The process begins with cyclopamine extracted from harvested Veratrum californicum which is taken through a series of alterations resulting in an analogue of the natural product cyclopamine, making IPI-926 the only compound in development/testing that is not fully synthetic.
One derivative of it, compound name IPI-926, is currently undergoing clinical trials for the treatment of various types of cancer, including hard-to-treat hematologic malignancies, chondrosarcoma, and pancreatic cancer.
Veratrum album | Veratrum | Veratrum viride | Veratrum nigrum | Veratrum californicum |